APUS

Apimeds Pharmaceuticals US
APUS

6 hedge funds and large institutions have $803K invested in Apimeds Pharmaceuticals US in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more capital invested

Capital invested by funds: $ → $

more ownership

Funds ownership: →

less funds holding

Funds holding: →

Holders
6
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$3.71M
2
+$550K
3
+$159K
4
UBS Group
UBS Group
Switzerland
+$62.2K

Top Sellers

1
-$44.6K
2
-$16
Name Holding Trade Value Shares
Change 		Change in
Stake
HTHT
1
Hemenway Trust Hemenway Trust
New Hampshire
$490K
VCML
2
VANGUARD CAPITAL MANAGEMENT LLC
Pennsylvania
$172K
Geode Capital Management
3
Geode Capital Management
Massachusetts
$71.7K
VFTC
4
VANGUARD FIDUCIARY TRUST CO
Pennsylvania
$43K
TSS
5
Two Sigma Securities
New York
$18.9K
UBS Group
6
UBS Group
Switzerland
$7.49K
Jane Street
7
Jane Street
New York
–
TRCT
8
Tower Research Capital (TRC)
New York
–